tiprankstipranks
AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
The Fly

AstraZeneca sees FY23 core EPS up high single to low double-digit percentage

Total revenue is expected to increase by a low-to-mid single-digit percentage. Excluding COVID-19 medicines, total revenue is expected to increase by a low double-digit percentage. Core EPS is expected to increase by a high single-digit to low double-digit percentage. Total revenue from COVID-19 medicines — Vaxzevria14 and COVID-19 mAbs15 — is expected to decline significantly in FY23, with minimal revenue from Vaxzevria.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AZN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles